General conditions for general recognition as safe, effective and not misbranded

CurrencyCurrent through May 31, 2023
Citation 21 C.F.R. §330.1

Get this document and AI-powered insights with a free trial of vLex and Vincent AI

Get Started for Free

Unlock full access with a free 7-day trial

Transform your legal research with vLex

  • Complete access to the largest collection of common law case law on one platform

  • Generate AI case summaries that instantly highlight key legal issues

  • Advanced search capabilities with precise filtering and sorting options

  • Comprehensive legal content with documents across 100+ jurisdictions

  • Trusted by 2 million professionals including top global firms

  • Access AI-Powered Research with Vincent AI: Natural language queries with verified citations

vLex

Unlock full access with a free 7-day trial

Transform your legal research with vLex

  • Complete access to the largest collection of common law case law on one platform

  • Generate AI case summaries that instantly highlight key legal issues

  • Advanced search capabilities with precise filtering and sorting options

  • Comprehensive legal content with documents across 100+ jurisdictions

  • Trusted by 2 million professionals including top global firms

  • Access AI-Powered Research with Vincent AI: Natural language queries with verified citations

vLex

Unlock full access with a free 7-day trial

Transform your legal research with vLex

  • Complete access to the largest collection of common law case law on one platform

  • Generate AI case summaries that instantly highlight key legal issues

  • Advanced search capabilities with precise filtering and sorting options

  • Comprehensive legal content with documents across 100+ jurisdictions

  • Trusted by 2 million professionals including top global firms

  • Access AI-Powered Research with Vincent AI: Natural language queries with verified citations

vLex

Unlock full access with a free 7-day trial

Transform your legal research with vLex

  • Complete access to the largest collection of common law case law on one platform

  • Generate AI case summaries that instantly highlight key legal issues

  • Advanced search capabilities with precise filtering and sorting options

  • Comprehensive legal content with documents across 100+ jurisdictions

  • Trusted by 2 million professionals including top global firms

  • Access AI-Powered Research with Vincent AI: Natural language queries with verified citations

vLex

Unlock full access with a free 7-day trial

Transform your legal research with vLex

  • Complete access to the largest collection of common law case law on one platform

  • Generate AI case summaries that instantly highlight key legal issues

  • Advanced search capabilities with precise filtering and sorting options

  • Comprehensive legal content with documents across 100+ jurisdictions

  • Trusted by 2 million professionals including top global firms

  • Access AI-Powered Research with Vincent AI: Natural language queries with verified citations

vLex

Unlock full access with a free 7-day trial

Transform your legal research with vLex

  • Complete access to the largest collection of common law case law on one platform

  • Generate AI case summaries that instantly highlight key legal issues

  • Advanced search capabilities with precise filtering and sorting options

  • Comprehensive legal content with documents across 100+ jurisdictions

  • Trusted by 2 million professionals including top global firms

  • Access AI-Powered Research with Vincent AI: Natural language queries with verified citations

vLex
3 cases
  • Lester v. CVS Pharm.
    • United States
    • U.S. District Court — Southern District of New York
    • March 27, 2024
    ...as safe and effective and is not misbranded if it meets each condition in this OTC monograph and each general condition established in 21 CFR 330.1.” See M003 § M003.1. The FDCA states that a “drug or device shall be deemed to be misbranded . . . [i]f its labeling is false or misleading in ......
  • Tobin v. Procter & Gamble Co.
    • United States
    • U.S. District Court — Northern District of California
    • April 9, 2024
    .... . . is not misbranded if it meets each of the conditions in [21 C.F.R. Part 341] and each of the general conditions established in § 330.1.” 21 C.F.R. § 341.1. Part provides a non-exclusive list of statements that may be used to describe cough and cold medications. 21 C.F.C. § 341.74(b). ......
  • Williams v. Galderma Labs.
    • United States
    • U.S. District Court — Northern District of Illinois
    • September 17, 2024
    ...as safe and effective and is not misbranded if it meets each of the conditions in this subpart and each general condition established in § 330.1 of this The relevant monograph for acne drugs lists BPO as a permitted active ingredient and does not require manufacturers to warn consumers of b......
2 firm's commentaries
  • CARES Act Dooms Claim Targeting the Marketing of “Infant” Acetaminophen
    • United States
    • LexBlog United States
    • May 20, 2021
    ...C.F.R. § 201.66. Under 21 C.F.R. § 330.1, an OTC drug “is generally recognized as safe and effective and is not misbranded if it meets each of the conditions contained in” 21 C.F.R. Part 330 “and each of the conditions contained in any applicable monograph.” The FDA explains that “an OTC mo......
  • OTC Drug User Facility Fees – Don’t Miss the Changes!
    • United States
    • JD Supra United States
    • December 31, 2020
    ...testing methodology or a safety-related change. [6] Section 744M(a)(2) of the FFDCA. [7] Section 744M(e)(2) of the FFDCA. Ann Begley 21 CFR 330.1 (or any successor regulations), Any other change specified by the FDA pursuant to an order. Everything else qualifies as a Tier 1 OMOR, which inc......